A Phase 2 interventional study of secukinumab and Placebo in Tendinopathy, sponsored by Novartis Pharmaceuticals. Completed at 12 sites in 5 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-10-08.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies in Tendinopathy with a site in United States — 15 open to participants now, 17 under way, none of them phase 3. Tendinopathy · United States.
Among the 99 studies in Tendinopathy with a site in United States, this one is the 21st largest by enrollment of the 89 interventional ones that give a count, is one of 10 that started in 2017, is one of 11 in phase 2, and was the 46th registered.
397 studies on the registry are indexed under Tendinopathy; 77 are open to participants now.
Browse Tendinopathy studies →15 of the 99 studies in Tendinopathy with a site in United States are open now. Recruiting first, the newest first:
Weill Medical College of Cornell University · Sites in United States
Ages 18–80
Joint & Vascular Institute · Sites in United States
Ages 25–80
The University of Texas Medical Branch, Galveston · Sites in United States
Ages 18+
University of Utah · Sites in United States
Ages 18+ · Healthy volunteers
Brigham and Women's Hospital · Sites in United States
Ages 21–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 47 Tendinopathy studies recruiting now, 17 (36%) set no upper age limit and 23 (49%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 12 · Phase 3 8 · Phase 4 15
First in 2002; this study’s year is marked. 10 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 96 is above the median of 48 across 332 interventional studies indexed under Tendinopathy.
Median enrollment 40 across the 89 interventional studies, 66 across the 10 observational. Of the 68 that completed or were terminated, 25 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 99 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 5 studies filed under Tendinopathy — fewer than ten, so there is no comparison to draw.
8 of the studies in Tendinopathy with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06160427Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)Connective Tissue Matrix for Rotator Cuff Tendinopathy | 2027-01-15 |
| NCT06095050Brigham and Women's HospitalEmbolization Treatment of Chronic Refractory Shoulder Tendinopathy | 2027-01-16 |
| NCT07642583Brooke Army Medical CenterDry Needling and Exercise for Mid-portion Achilles Tendinopathy | 2027-03-30 |
| NCT07553273The University of Texas Medical Branch, GalvestonVibratory Anesthesia on Pain Following Corticosteroid Injections | 2027-04 |
| NCT02600910The University of Texas Medical Branch, GalvestonNatural History of Shoulder Pathology in Manual Wheelchair Users | 2027-06 |
Add all 8 to your calendar (.ics) → With an account.
Among the 99 studies in Tendinopathy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a randomized, double-blind, placebo-controlled, multi-center, Phase II study of s.c. secukinumab 300 mg in 98 randomized patients with overuse rotator-cuff tendinopathy without systemic inflammatory disease.
This was a randomized, double-blind, placebo-controlled, multi-center, Phase II study of s.c. secukinumab 300 mg in 98 randomized patients with overuse rotator-cuff tendinopathy without systemic inflammatory disease and refractory to NSAIDs/acetaminophen, physiotherapy or corticosteroids.
The study consisted of a 4-week screening period, a 2-week run-in period, a 12-week treatment period and a 12-week follow-up period after last treatment. The population consisted of patients with unilateral overuse (non-systemic inflammatory) shoulder tendinopathy, 18 - 65 years of age.
Safety assessments included physical examinations, ECGs, vital signs, standard clinical laboratory evaluations (hematology, blood chemistry, and urinalysis), adverse event and serious adverse event monitoring.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Presence of unilateral rotator cuff tendinopathy with:
Exclusion Criteria:
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AIN457 300 mg subcutaneously (s.c.) for 12 weeks
Drug: secukinumab
Placebo subcutaneously for 12 weeks
Other: Placebo
AIN457 300 mg subcutaneously for 12 weeks
Also known as: AIN457
Placebo to match AIN457 subcutaneously for 12 weeks
The Western Ontario Rotator Cuff (WORC) Patient Reported Outcome (PRO) Score at Week 14 in All Patients - Statistical Analysis Results of Total WORC Scores at Week 14
WORC PRO score at week 14. The WORC Index consists of 21 items divided into 5 Domains: Physical Symptoms (6 items), Sport/Recreation (4 items), Work Function (4 items), Lifestyle Function (4 items) and Emotional Function (3 items). The total scores and sub scores used were the percentages of the normal scores with 0 being worst and 100 being best. All Patients - Statistical analysis results of WORC scores at Week 14
Time frame: Week 14 (Day 99)
The Western Ontario Rotator Cuff (WORC) Patient Reported Outcome (PRO) Scores Over Time in All Patients
WORC score at Days 15, 29, 57, 85, 127, and End of Study (day 169). The scale range for WORC total score is 0-100, 0 being the worst possible outcome (highly symptomatic patient) and 100 being the best possible outcome (asymptomatic patient)
Time frame: Days 15, 29, 57, 85, 127, and End of Study
Disability of Arm, Shoulder and Hand Questionnaire Score (QuickDASH) Over Time
Patient Reported Outcome: Disability of Arm, Shoulder and Hand (QuickDASH) This questionnaire asks about symptoms as well participant's ability to do certain activities - ranging from 1 (No difficulty) to 5 (Unable). The scale range for QuickDASH total score is 0-100, 0 being the best possible outcome and 100 being the worst possible outcome
Time frame: Days 15, 29, 57, 85, 99, 127, and End of Study
American Shoulder and Elbow Surgeons (ASES) Score Over Time
Patient Reported Outcome: American Shoulder and Elbow Surgeons Shoulder Evaluation Form (ASES) score is self-administered and has 17 questions in the areas of shoulder symptoms and functions. The ASES total score ranges from 0 to 100 (best).
Time frame: Days 15, 29, 57, 85, 99, 127, and End of Study
Your Health Today Score Over Time
Patient Reported Outcome: Statistical analysis results of EQ-5D-5L for Your health Today questionnaire, which reflects how good or bad the subjets Health is on a scale from 0 (worst health) to 100 (best health).
Time frame: Days 15, 29, 57, 85, 99, 127, and End of Study
EQ-5D-5L Index Score Over Time
Patient Reported Outcome: Statistical analysis results of EQ-5D-5L Index score, which contains 5 items to assess Health Status (mobility, self-care, usual activity, pain/discomfort, and anxiety/depression). Overall scores range from 0 to 1 with lower scores representing a higher level of dysfunction.
Time frame: Days 15, 29, 57, 85, 99, 127 and End of Study
Pain Score Over Time Using a VAS Scale
Pain intensity is assessed by a Visual Analog Scale (VAS) which is measured on a 100mm line that represents a continuum between "no pain" and "worst pain". The scale range for pain score is 0-100, 0 being the best possible outcome (no pain) and 100 being the worst possible outcome (worst pain).
Time frame: Days 15, 29, 57, 85, 99, 127 and End of Study
Patient Global Assessment (PGA) Score Over Time Using a VAS Scale
The patient's global assessment of disease activity is performed using a 100 mm Visual Analog Scale (VAS) ranging from "no activity" to "most active" in the last 24 hours. The scale range for PGA score is 0-100, 0 being the best possible outcome (no disease activity) and 100 being the worst possible outcome (maximal disease activity).
Time frame: Days 15, 29, 57, 85, 99, 127 and End of Study
Physician Global Assessment (PhGA) Score Using a VAS Scale Over Time
Physician global assessment (PhGA) score using a VAS scale (considering the last 24 hours). The scale range for PhGA score is 0-100, 0 being the best possible outcome (no disease activity) and 100 being the worst possible outcome (maximal disease activity).
Time frame: Days 15, 29, 57, 85, 99, 127 and End of Study
Pharmacokinetics - Cmin
Mean trough concentrations Cmin is a pharmacokinetics term for the minimum blood plasma concentration reached by a drug prior to administration of a second dose (mass/volume) Serum trough concentrations of secukinumab 300 mg group was measured at Days 1, 29, 85 and EoS
Time frame: Days 1, 29, 85 and EoS (End of Study)
Immunogenicity Assessment - Treatment Emergent ADAs
Number of Participants with Treatment emergent Anti-secukinumab antibodies
Time frame: Day 1 and EoS
Number of Participants With Tendinosis Grade Score 1, 2 or 3 Measured by Magnetic Resonance Imaging (MRI) Sein Scores
Assessment of structural changes in the rotator cuff tendinopathy over time The MRI Sein score was used to grade supraspinatus tendinosis using a modified 4-point scale from 0 to 3 and changes in grading over time were captured in the shift table. Grade 0 is normal, grade 1 is mild, Grade 2 is moderate and grade 3 is marked tendinosis. In this Sein score assessment, only data from Day 99 and baseline could be compared, as only those two time points were double read and adjudicated in case the 2 readers had different results. At any other time-points (Day 57 and EOS), images were assessed only by one reader and thus could not be compared to baseline.
Time frame: Baseline and Day 99
Of all patients randomized (N= 98; 100%) in the study, a total of 96 patients (98%) were dosed (49 patients in the secukinumab 300 mg group and 47 patients in the placebo group)
| Milestone | Secukinumab | Placebo |
|---|---|---|
| Started | 49 | 47 |
| Completed | 46 | 44 |
| Not completed | 3 | 3 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Milestone | Secukinumab | Placebo |
|---|---|---|
| Started | 46 | 44 |
| Completed | 46 | 42 |
| Not completed | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 2 |
WORC PRO score at week 14. The WORC Index consists of 21 items divided into 5 Domains: Physical Symptoms (6 items), Sport/Recreation (4 items), Work Function (4 items), Lifestyle Function (4 items) and Emotional Function (3 items). The total scores and sub scores used were the percentages of the normal scores with 0 being worst and 100 being best. All Patients - Statistical analysis results of WORC scores at Week 14
| Scores on a scale | Secukinumab | Placebo |
|---|---|---|
| The Western Ontario Rotator Cuff (WORC) Patient Reported Outcome (PRO) Score at Week 14 in All Patients - Statistical Analysis Results of Total WORC Scores at Week 14 | 37.00 (30.10 to 43.90) | 37.77 (30.40 to 45.15) |
WORC score at Days 15, 29, 57, 85, 127, and End of Study (day 169). The scale range for WORC total score is 0-100, 0 being the worst possible outcome (highly symptomatic patient) and 100 being the best possible outcome (asymptomatic patient)
| Scores on a scale | Secukinumab | Placebo |
|---|---|---|
| Day 15 | 12.39 (6.99 to 17.79) | 8.42 (2.66 to 14.18) |
| Day 29 | 22.35 (16.38 to 28.32) | 19.49 (13.11 to 25.86) |
| Day 57 | 28.74 (22.19 to 35.29) | 30.11 (23.08 to 37.13) |
| Day 85 | 34.86 (28.18 to 41.53) | 33.48 (26.35 to 40.61) |
| Day 127 | 41.86 (34.96 to 48.77) | 38.50 (31.12 to 45.88) |
| End of Study | 43.41 (36.21 to 50.61) | 40.97 (33.27 to 48.66) |
Patient Reported Outcome: Disability of Arm, Shoulder and Hand (QuickDASH) This questionnaire asks about symptoms as well participant's ability to do certain activities - ranging from 1 (No difficulty) to 5 (Unable). The scale range for QuickDASH total score is 0-100, 0 being the best possible outcome and 100 being the worst possible outcome
| Scores on a scale | Secukinumab | Placebo |
|---|---|---|
| Day 15 | -11.64 (-16.14 to -7.14) | -8.23 (-13.02 to -3.44) |
| Day 29 | -18.31 (-23.20 to -13.41) | -16.95 (-22.18 to -11.73) |
| Day 57 | -22.43 (-27.55 to -17.30) | -24.01 (-29.49 to -18.52) |
| Day 85 | -28.14 (-33.55 to -22.73) | -27.22 (-32.98 to -21.45) |
| Day 99 | -29.45 (-34.72 to -24.19) | -30.69 (-36.30 to -25.07) |
| Day 127 | -32.86 (-38.26 to -27.46) | -31.99 (-37.75 to -26.23) |
| End of Study | -33.89 (-39.27 to -28.50) | -35.40 (-41.13 to -29.67) |
Patient Reported Outcome: American Shoulder and Elbow Surgeons Shoulder Evaluation Form (ASES) score is self-administered and has 17 questions in the areas of shoulder symptoms and functions. The ASES total score ranges from 0 to 100 (best).
| Scores on a scale | Secukinumab | Placebo |
|---|---|---|
| Day 15 | 8.66 (3.98 to 13.33) | 5.26 (0.26 to 10.25) |
| Day 29 | 17.53 (12.35 to 22.71) | 14.37 (8.82 to 19.92) |
| Day 57 | 24.15 (18.34 to 29.96) | 22.56 (16.31 to 28.81) |
| Day 85 | 30.50 (24.51 to 36.50) | 26.97 (20.51 to 33.43) |
| Day 99 | 31.29 (25.28 to 37.31) | 27.79 (21.33 to 34.26) |
| Day 127 | 34.92 (28.80 to 41.05) | 32.94 (26.33 to 39.56) |
| End of Study | 37.29 (30.97 to 43.62) | 36.15 (29.33 to 42.97) |
Patient Reported Outcome: Statistical analysis results of EQ-5D-5L for Your health Today questionnaire, which reflects how good or bad the subjets Health is on a scale from 0 (worst health) to 100 (best health).
| Scores on a scale | Secukinumab | Placebo |
|---|---|---|
| Day 15 | -0.22 (-4.02 to 3.58) | 0.02 (-4.02 to 4.07) |
| Day 29 | 3.27 (-0.71 to 7.25) | 3.56 (-0.69 to 7.81) |
| Day 57 | 3.19 (-1.07 to 7.45) | 9.02 (4.45 to 13.59) |
| Day 85 | 7.36 (2.84 to 11.89) | 7.79 (2.96 to 12.62) |
| Day 99 | 8.75 (4.13 to 13.38) | 10.01 (5.09 to 14.94) |
| Day 127 | 9.55 (5.29 to 13.80) | 13.59 (9.05 to 18.13) |
| End of Study | 10.22 (4.84 to 15.60) | 12.13 (6.36 to 17.89) |
Patient Reported Outcome: Statistical analysis results of EQ-5D-5L Index score, which contains 5 items to assess Health Status (mobility, self-care, usual activity, pain/discomfort, and anxiety/depression). Overall scores range from 0 to 1 with lower scores representing a higher level of dysfunction.
| Scores on a scale | Secukinumab | Placebo |
|---|---|---|
| Day 15 | 0.07 (0.05 to 0.10) | 0.04 (0.01 to 0.07) |
| Day 29 | 0.10 (0.07 to 0.13) | 0.09 (0.05 to 0.12) |
| Day 57 | 0.12 (0.09 to 0.15) | 0.11 (0.08 to 0.15) |
| Day 85 | 0.16 (0.13 to 0.19) | 0.14 (0.10 to 0.18) |
| Day 99 | 0.16 (0.13 to 0.20) | 0.15 (0.11 to 0.19) |
| Day 127 | 0.19 (0.15 to 0.23) | 0.17 (0.13 to 0.21) |
| End of Study | 0.19 (0.16 to 0.23) | 0.18 (0.14 to 0.22) |
Pain intensity is assessed by a Visual Analog Scale (VAS) which is measured on a 100mm line that represents a continuum between "no pain" and "worst pain". The scale range for pain score is 0-100, 0 being the best possible outcome (no pain) and 100 being the worst possible outcome (worst pain).
| Scores on a scale | Secukinumab | Placebo |
|---|---|---|
| Day 15 | -12.11 (-19.52 to -4.70) | -9.50 (-17.30 to -1.71) |
| Day 29 | -26.04 (-33.97 to -18.11) | -23.13 (-31.52 to -14.74) |
| Day 57 | -35.52 (-43.67 to -27.37) | -32.83 (-41.52 to -24.15) |
| Day 85 | -42.63 (-50.88 to -34.38) | -37.97 (-46.74 to -29.21) |
| Day 99 | -46.11 (-54.10 to -38.12) | -40.56 (-49.00 to -32.11) |
| Day 127 | -49.44 (-57.45 to -41.44) | -45.27 (-53.75 to -36.79) |
| End of Study | -52.23 (-60.31 to -44.14) | -50.74 (-59.40 to -42.08) |
The patient's global assessment of disease activity is performed using a 100 mm Visual Analog Scale (VAS) ranging from "no activity" to "most active" in the last 24 hours. The scale range for PGA score is 0-100, 0 being the best possible outcome (no disease activity) and 100 being the worst possible outcome (maximal disease activity).
| Scores on a scale | Secukinumab | Placebo |
|---|---|---|
| Day 15 | -6.33 (-13.44 to 0.79) | -8.09 (-15.79 to -0.38) |
| Day 29 | -22.25 (-29.68 to -14.82) | -16.38 (-24.43 to -8.33) |
| Day 57 | -29.40 (-37.06 to -21.74) | -25.69 (-34.04 to -17.34) |
| Day 85 | -37.57 (-45.01 to -30.12) | -31.75 (-39.79 to -23.72) |
| Day 99 | -38.43 (-45.88 to -30.97) | -35.10 (-43.14 to -27.07) |
| Day 127 | -43.78 (-51.23 to -36.33) | -38.32 (-46.37 to -30.26) |
| End of Study | -47.72 (-55.15 to -40.28) | -39.43 (-47.45 to -31.40) |
Physician global assessment (PhGA) score using a VAS scale (considering the last 24 hours). The scale range for PhGA score is 0-100, 0 being the best possible outcome (no disease activity) and 100 being the worst possible outcome (maximal disease activity).
| Score on a scale | Secukinumab | Placebo |
|---|---|---|
| Day 15 | -13.99 (-20.22 to -7.75) | -9.11 (-15.80 to -2.42) |
| Day 29 | -25.01 (-31.51 to -18.50) | -19.42 (-26.42 to -12.43) |
| Day 57 | -30.78 (-37.57 to -23.99) | -27.83 (-35.13 to -20.53) |
| Day 85 | -33.42 (-40.68 to -26.16) | -37.88 (-45.66 to -30.11) |
| Day 99 | -35.72 (-42.66 to -28.79) | -41.73 (-49.15 to -34.31) |
| Day 127 | -41.72 (-48.32 to -35.12) | -44.18 (-51.28 to -37.08) |
| End of Study | -44.64 (-51.86 to -37.41) | -44.26 (-52.02 to -36.51) |
Mean trough concentrations Cmin is a pharmacokinetics term for the minimum blood plasma concentration reached by a drug prior to administration of a second dose (mass/volume) Serum trough concentrations of secukinumab 300 mg group was measured at Days 1, 29, 85 and EoS
| ug/mL | Secukinumab |
|---|---|
| Mean trough concentration after first 4 wkly doses | 90.4 ± 30.7 |
| Week 12 | 13.2 ± 6.67 |
Number of Participants with Treatment emergent Anti-secukinumab antibodies
| Participants | Secukinumab | Placebo |
|---|---|---|
| Day 1 | 0 | 1 |
| End of Study | 0 | 0 |
Assessment of structural changes in the rotator cuff tendinopathy over time The MRI Sein score was used to grade supraspinatus tendinosis using a modified 4-point scale from 0 to 3 and changes in grading over time were captured in the shift table. Grade 0 is normal, grade 1 is mild, Grade 2 is moderate and grade 3 is marked tendinosis. In this Sein score assessment, only data from Day 99 and baseline could be compared, as only those two time points were double read and adjudicated in case the 2 readers had different results. At any other time-points (Day 57 and EOS), images were assessed only by one reader and thus could not be compared to baseline.
| participants | Secukinumab | Placebo |
|---|---|---|
| Baseline grade 1 | 31 | 25 |
| Baseline grade 2 | 11 | 10 |
| Baseline grade 3 | 3 | 3 |
| Day 99 grade 1 | 31 | 26 |
| Day 99 grade 2 | 11 | 9 |
| Day 99 grade 3 | 3 | 3 |
Collected over Approximately 40 weeks: 15 Dec 2017 through 17 Oct 2019. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AIN457 300 mg s.c. | 0/49 (0%) | 0/49 (0%) | 36/49 (73.5%) |
| Placebo | 0/47 (0%) | 0/47 (0%) | 34/47 (72.3%) |
| Event | AIN457 300 mg s.c. | Placebo |
|---|---|---|
| NasopharyngitisInfections and infestations | 8/49 | 5/47 |
| HeadacheNervous system disorders | 7/49 | 7/47 |
| NauseaGastrointestinal disorders | 6/49 | 5/47 |
| Upper respiratory tract infectionInfections and infestations | 2/49 | 4/47 |
| Back painMusculoskeletal and connective tissue disorders | 1/49 | 4/47 |
| NeutropeniaBlood and lymphatic system disorders | 3/49 | 1/47 |
| Fungal skin infectionInfections and infestations | 3/49 | 0/47 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 3/49 | 1/47 |
| Neck painMusculoskeletal and connective tissue disorders | 3/49 | 1/47 |
| FatigueGeneral disorders | 1/49 | 2/47 |
The safety analysis set (SAS) included all subjects that received any study drug.
| Age, Continuous(years) | Secukinumab | Placebo | Total |
|---|---|---|---|
| Mean | 44.8 ± 11.51 | 49.1 ± 10.56 | 46.9 ± 11.20 |
| Sex: Female, Male(Participants) | Secukinumab | Placebo | Total |
|---|---|---|---|
| Female | 17 | 23 | 40 |
| Male | 32 | 24 | 56 |
| Race/Ethnicity, Customized(Participants) | Secukinumab | Placebo | Total |
|---|---|---|---|
| Asian | 1 | 0 | 1 |
| Black or African American | 3 | 1 | 4 |
| White | 43 | 45 | 88 |
| Unknown | 1 | 0 | 1 |
| Other | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Dec 2017 to primary completion in Aug 2019, 19 months.
Results were first posted in Dec 2020, 1 year 4 months after primary completion. A results delay was requested in Feb 2020.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab